Jai Rautela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jai Rautela has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas D. Huntington
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
14 shared publications - Belinda S. Parker
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
9 shared publications Nikola Baschuk
9 shared publications- Stephen Laurence Nutt
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
6 shared publications - Andreas Möller
Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia
5 shared publications Bradley N. Bidwell
5 shared publications
Latest Publications
- Open Access
- 23 May 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (7) , 699-711
Adjusting the scope of natural killer cells in cancer therapy
Natural killer (NK) cells have evolved to detect abnormalities in tissues arising from infection with pathogens, genomic damage, or transformation and respond rapidly to the production of potent proinflammatory and cytolytic mediators. While this acute proinflammatory response is highly efficient at orchestrating sterilizing immunity to pathogens in a matter of days, cellular transformation often avoids the innate detection mechanisms of NK cells. When cellular transformation results in malignancy, tumor cells and/or the tumor microenvironment can evolve additional mechanisms to circumvent NK cell responses, and cancer is now a dominant disease burden worldwide. Here, we review recent advances in our understanding of the combined relationship between malignancies and natural killer (NK) cells, learn from recent clinical efforts in therapeutically targeting natural killer (NK) cells in cancer and outline some emerging therapeutic concepts that aim to improve the innate immune response against cancer.
- 23 May 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (7) , 699-711
Open AccessAdjusting the scope of natural killer cells in cancer therapy
Natural killer (NK) cells have evolved to detect abnormalities in tissues arising from infection with pathogens, genomic damage, or transformation and respond rapidly to the production of potent proinflammatory and cytolytic mediators. While this acute proinflammatory response is highly efficient at orchestrating sterilizing immunity to pathogens in a matter of days, cellular transformation often avoids the innate detection mechanisms of NK cells. When cellular transformation results in malignancy, tumor cells and/or the tumor microenvironment can evolve additional mechanisms to circumvent NK cell responses, and cancer is now a dominant disease burden worldwide. Here, we review recent advances in our understanding of the combined relationship between malignancies and natural killer (NK) cells, learn from recent clinical efforts in therapeutically targeting natural killer (NK) cells in cancer and outline some emerging therapeutic concepts that aim to improve the innate immune response against cancer.
- 5 January 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (2) , 240-255
IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development
Ikaros transcription factors are essential for adaptive lymphocyte function, yet their role in innate lymphopoiesis is unknown. Using conditional genetic inactivation, we show that Ikzf1/Ikaros is essential for normal natural killer (NK) cell lymphopoiesis and IKZF1 directly represses Cish, a negative regulator of interleukin-15 receptor resulting in impaired interleukin-15 receptor signaling. Both Bcl2l11 and BIM levels, and intrinsic apoptosis were increased in Ikzf1-null NK cells, which in part accounts for NK lymphopenia as both were restored to normal levels when Ikzf1 and Bcl2l11 were co-deleted. Ikzf1-null NK cells presented extensive transcriptional alterations with reduced AP-1 transcriptional complex expression and increased expression of Ikzf2/Helios and Ikzf3/Aiolos. IKZF1 and IKZF3 directly bound AP-1 family members and deletion of both Ikzf1 and Ikzf3 in NK cells resulted in further reductions in Jun/Fos expression and complete loss of peripheral NK cells. Collectively, we show that Ikaros family members are important regulators of apoptosis, cytokine responsiveness and AP-1 transcriptional activity.
- 5 January 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (2) , 240-255
IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development
Ikaros transcription factors are essential for adaptive lymphocyte function, yet their role in innate lymphopoiesis is unknown. Using conditional genetic inactivation, we show that Ikzf1/Ikaros is essential for normal natural killer (NK) cell lymphopoiesis and IKZF1 directly represses Cish, a negative regulator of interleukin-15 receptor resulting in impaired interleukin-15 receptor signaling. Both Bcl2l11 and BIM levels, and intrinsic apoptosis were increased in Ikzf1-null NK cells, which in part accounts for NK lymphopenia as both were restored to normal levels when Ikzf1 and Bcl2l11 were co-deleted. Ikzf1-null NK cells presented extensive transcriptional alterations with reduced AP-1 transcriptional complex expression and increased expression of Ikzf2/Helios and Ikzf3/Aiolos. IKZF1 and IKZF3 directly bound AP-1 family members and deletion of both Ikzf1 and Ikzf3 in NK cells resulted in further reductions in Jun/Fos expression and complete loss of peripheral NK cells. Collectively, we show that Ikaros family members are important regulators of apoptosis, cytokine responsiveness and AP-1 transcriptional activity.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC